menu search

APRE / All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read More
Posted: Apr 4 2023, 13:42
Author Name: Zacks Investment Research
Views: 082947

APRE News  

All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

By Zacks Investment Research
April 4, 2023

All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target

By InvestorPlace
July 8, 2022

Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target

Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here's why this is significant for the biotech sector. more_horizontal


Search within

Pages Search Results: